Europe — EMA
Ontozry (Cenobamate)
Cenobamate, the active ingredient in Ontozry, is a novel antiepileptic presented as a tablet for oral use. It is indicated for the treatment of partial-onset seizures in adults.
Request sourcing
What is Cenobamate?
Cenobamate, the active ingredient in Ontozry, is a novel antiepileptic presented as a tablet for oral use. It is indicated for the treatment of partial-onset seizures in adults. GNH USA supplies Ontozry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.
GNH USA supplies Ontozry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.
What is Cenobamate used for?
Ontozry is an antiepileptic drug that targets seizure activity in the central nervous system.
- Partial-onset seizures: Reduces seizure frequency in adults with focal epilepsy. - Adjunct therapy: Used alongside other antiseizure medications to improve overall seizure control. - Refractory epilepsy: May provide additional benefit when seizures are not controlled by first‑line agents.
What are the side effects of Cenobamate?
Side effects reported with cenobamide include both common and less frequent reactions.
Common Side Effects: - Dizziness. - Fatigue. - Headache. - Nausea. - Somnolence.
Serious or Rare Side Effects: - Stevens‑Stevens Stevens Ste . - Drug‑induced liver . - Severe rash . - Blood dyscrasia. - Suicidal thoughts . - QT .
What precautions apply to Cenobamate?
When …
- g g t d d t d ullet ewline
t ewline ext ewline \
